Gram Research analysis of a 2026 literature review found that resmetirom, the first approved treatment for MASH in the United States, appears to work in everyday practice as it did in clinical trials. Early real-world reports look encouraging, and doctors increasingly rely on noninvasive tests to find and track patients.
Fatty liver disease is the most common chronic liver disease worldwide, and in some people it progresses to a more serious form called MASH, which can scar the liver. According to research reviewed by Gram, resmetirom became the first medicine approved in the United States in 2024 to treat adults with MASH and moderate to advanced scarring, when used alongside a healthy diet and regular exercise. This review of published reports and conference materials through mid-2026 found that early real-world results from US patients appear encouraging and match the benefits seen in the large clinical trial. Doctors are also increasingly using simple blood tests and imaging scans instead of liver biopsies to find and track patients. The review suggests that lifestyle changes alone may soon be joined by a liver-targeted medicine as a standard option for managing this condition.
Key Statistics
A 2026 targeted literature review published in Expert Review of Gastroenterology and Hepatology found that MASH, the more serious form of fatty liver disease, develops in up to 30% of people with the broader condition.
According to research reviewed by Gram, resmetirom received accelerated conditional US approval in 2024 as the first drug for adults with MASH and moderate to advanced liver fibrosis, used alongside diet and exercise.
A 2026 literature review searched PubMed, Embase, and Europe PMC for English-language reports through March 31, 2026, and manually searched congress materials through June 30, 2026, to assess resmetirom use in the United States.
The Quick Take
- What they studied: Researchers asked how well resmetirom, a newly approved liver medicine, is working for patients in everyday US medical care, outside of tightly controlled clinical trials.
- Who participated: The review did not enroll patients itself. It gathered published studies, reports, and conference presentations in English from major medical databases, and the total number of patients across those sources was not stated.
- Key finding: Early real-world reports from US clinics show results that appear to support the benefits seen in the main clinical trial, though the review did not give a single combined percentage. It also found that doctors are relying more on noninvasive tests to identify and monitor patients.
- What it means for you: If you have fatty liver disease that has progressed to MASH with moderate to advanced scarring, resmetirom may be an option to discuss with your doctor. It works best alongside diet and exercise, and it is not a replacement for those habits. Your doctor can judge whether it fits your situation.
The Research Details
This is a targeted literature review, which means the authors searched medical research databases for relevant reports rather than running a new experiment. They looked through PubMed, Embase, and Europe PMC for articles published in English through March 31, 2026. They also searched conference materials from medical meetings through June 30, 2026.
The goal was to collect what is currently known about how resmetirom performs in everyday medical practice in the United States. Real-world reports come from patients treated in ordinary clinics, so they show how a medicine works outside the strict rules of a clinical trial.
Because the authors gathered and summarized existing material, the strength of the conclusions depends on the quality of the reports they found. Many real-world reports are small or early, so they are useful for spotting trends but not for proving results.
A literature review is a helpful way to get a broad picture of a new treatment when many early reports are scattered across journals and conferences. By combining them, the authors can show whether real-world experience matches what the main trial found.
This approach is especially useful for a medicine approved only recently. The main clinical trial followed carefully selected patients, while everyday use includes people with other health conditions, different ages, and different medications. Looking at this wider group helps show whether the benefits carry over.
The review focuses on current evidence and includes conference materials, which can contain results not yet published in full journals. Conference reports are usually less thoroughly checked than peer-reviewed papers, so they should be read with some caution.
The review does not state how many patients were included or how the authors rated the quality of each report. Readers should treat the findings as an early snapshot rather than a definitive verdict on how well the medicine works.
What the Results Show
The review found that early real-world data on resmetirom in the United States are encouraging. These early reports appear to support the liver benefits seen in the phase 3 MAESTRO-NASH trial, which was the large study used to win approval for the medicine.
Resmetirom works by acting on thyroid hormone receptors in the liver. It is designed to target the liver directly, which is a different approach from most other treatments for fatty liver disease. Because it is meant to be used with diet and exercise, it is best viewed as an addition to lifestyle changes rather than a stand-alone fix.
The authors also describe a shift in how doctors find and follow patients. Instead of relying mainly on liver biopsies, which are procedures that remove a small tissue sample, clinicians are increasingly using noninvasive tests such as blood markers and imaging scans to identify who has MASH and to monitor changes over time. This makes it easier to check progress without repeated surgery-like procedures.
The review notes that MASH can progress in up to 30% of people who have the broader fatty liver condition, which highlights why earlier identification matters. Noninvasive testing may help find these people sooner, so that they can be considered for treatment before significant scarring develops.
The authors also describe the broader treatment landscape changing. For years, lifestyle changes such as weight loss, healthier eating, and more physical activity were the main approach. The availability of a liver-directed medicine now adds a new option for patients who meet the criteria.
Before resmetirom, there was no approved medicine specifically for MASH, so most people were advised to focus on lifestyle changes. The review suggests that real-world use of resmetirom is moving the field toward a treatment that acts directly on the liver. Early US experience appears to match the main trial, which is a reassuring sign, though long-term data are still limited.
The review did not report how many patients were included in the studies it summarized, so it is hard to judge how much weight the evidence deserves. Many real-world reports are early, small, or presented only at conferences, which means they may change as fuller data become available.
The search only included reports in English, so useful studies published in other languages may have been missed. Also, real-world reports can be affected by who gets prescribed the medicine and how closely they are followed, which can make results look better or worse than they truly are.
Finally, the review is a summary of existing material rather than a new experiment, so it cannot prove cause and effect on its own. Long-term safety and benefits, such as effects on liver disease outcomes over many years, still need more research.
The Bottom Line
Research shows that resmetirom is an approved option for adults with MASH and moderate to advanced liver scarring, used together with diet and exercise. Confidence is moderate: the approval rests on a major clinical trial, and early real-world reports appear to support those results, but long-term data are still limited.
Noninvasive testing is a reasonable first step for identifying and monitoring people with fatty liver disease, based on current clinical practice trends described in the review. Lifestyle changes remain a foundation of care and should continue alongside any medicine.
Adults who have been diagnosed with MASH and have moderate to advanced liver scarring should discuss resmetirom with their doctor. People with fatty liver disease who have not yet been evaluated may also benefit from asking about noninvasive testing.
People without a MASH diagnosis, children, and those who are pregnant or planning pregnancy should not use this review to make decisions about this medicine without medical guidance. Anyone already taking other liver or thyroid-related medicines should check with a doctor first.
Liver changes develop slowly, so benefits from any liver treatment are usually measured over months to years rather than days or weeks. Your doctor will likely recheck blood tests or imaging at set intervals to see whether the medicine is helping. Expect gradual changes, and keep in mind that results vary from person to person.
Frequently Asked Questions
What is resmetirom and what is it used for?
Resmetirom is a medicine approved in the United States in 2024 for adults with MASH, a serious form of fatty liver disease, and moderate to advanced liver scarring. It is used together with a healthy diet and regular exercise to help manage the condition.
Does resmetirom work in real-world patients as well as in clinical trials?
According to research reviewed by Gram, early real-world reports from US patients appear to support the benefits seen in the main phase 3 trial, MAESTRO-NASH. Researchers note that long-term data are still limited, so results should be monitored over time.
How common is MASH, and can fatty liver disease get worse?
Fatty liver disease is the most common chronic liver disease globally. The review reports that it progresses to MASH in up to 30% of affected individuals, which is why early identification and monitoring matter.
Do I need a liver biopsy to find out if I have MASH?
Not necessarily. The review notes that clinicians are increasingly using noninvasive tests, such as blood markers and imaging scans, to identify patients with MASH and track their progress over time. Your doctor can explain which tests fit your situation.
Want to Apply This Research?
- Log your weight once per week at the same time of day, and record weekly minutes of physical activity along with the number of days you ate according to your plan. Also note any scheduled liver blood test results and imaging dates in the app so you can see trends over time.
- Set a weekly goal of at least 150 minutes of moderate activity, such as brisk walking, and track it in the app. Use the app’s reminders to plan balanced meals with vegetables, lean protein, and whole grains, and review your weekly log with your care team.
- Keep a monthly summary of weight, activity, meal consistency, and any side effects you notice, and bring it to each appointment. Over several months, look for steady patterns rather than single readings, and update your doctor whenever your routine or medicines change.
This article summarizes a literature review about resmetirom and is for general education only. It is not medical advice and does not replace consultation with a doctor or liver specialist. Resmetirom is a prescription medicine with possible side effects and drug interactions, and treatment decisions should be made with a qualified healthcare professional who knows your full medical history.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.